Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.
- DOI
- 10.1186/s12885-022-10427-4
- Published
- 2024 Jul 25
- Container
- BMC cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12885-022-10427-4,
title = {Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.},
author = {Boyer M and Hui R and Urban D and Clingan P and Su WC and Devaux C and Gadgeel S and Garassino M and Leopold L and Daniel J and Munteanu MC and Samkari A and Luo Y and Abreu DR},
year = {2024},
journal = {BMC cancer},
doi = {10.1186/s12885-022-10427-4},
url = {https://doi.org/10.1186/s12885-022-10427-4}
}RIS
TY - JOUR TI - Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study. AU - Boyer M AU - Hui R AU - Urban D AU - Clingan P AU - Su WC AU - Devaux C AU - Gadgeel S AU - Garassino M AU - Leopold L AU - Daniel J AU - Munteanu MC AU - Samkari A AU - Luo Y AU - Abreu DR PY - 2024 JO - BMC cancer DO - 10.1186/s12885-022-10427-4 UR - https://doi.org/10.1186/s12885-022-10427-4 ER -
APA
M, B., R, H., D, U., P, C., WC, S., C, D., S, G., M, G., L, L., J, D., MC, M., A, S., Y, L., & DR, A. (2024). Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study.. BMC cancer. https://doi.org/10.1186/s12885-022-10427-4
Source records
- pubmed · retrieved 2026-09-26T00:23:46.540Z